Global Companion Biomarker Market to Catapult to $319 Million by 2018

Wednesday 20 November 2013, Amsterdam

Global Companion Biomarker Market to Catapult to $319 Million by 2018
ASDReports.com cites in its newly published “Companion Biomarkers in Drug Development” report that the global companion biomarker market will catapult to $319 million by 2018.

Companion biomarkers can be categorized into four main therapeutic areas: oncology, cardiovascular, neurology and autoimmune. Oncology is the largest segment, commanding 30% of the market. Market opportunities for companion biomarkers are focused in drug development targets, drug development efficacy and clinical end points. Using companion biomarkers, the $883 billion global pharmaceutical market yields safer and more efficacious drug products, reduces clinical trial and development costs, improves post-marketing safety profiles and salvages therapies that otherwise would not be granted approval.

The “Companion Biomarkers in Drug Development” report covers:

•    DNA Microarrays
•    Antibody Microarrays
•    Peptide Microarrays
•    Peptide MHC Microarrays
•    Tissue Microarrays
•    GeneChip Probe Array Technology
•    Multiple Reaction Monitoring Assays (MRMs)
•    C-KIT (CD117) Expression
•    CYP2C19 Variants
•    CYP2C9 Variants
•    CYP2D6 Variants
•    Kidney Toxicity
•    Hepatotoxicity
    
The “Companion Biomarkers in Drug Development” report examines companies manufacturing companion biomarker equipment and supplies in the world. Companies covered include: Abbott, Accelrys, Almac, Ananomouse, ArrayIt, AstraZeneca, Axontologic, BD, Bioalma, BioCat, BioData, Biodesix, BioForce Nanosciences, BioGenex, BioMérieux, Bio-Rad, Biotrin, BioWisdom, Caliper Life, Caprion Proteomics, Cepheid, Clontech, Corimbia, Covance, CyVera, Dako, DiagnoSwiss, DNAStar, Eli Lilly, ePitope Informatics, Eurogentec, Fujitsu, GEcare, Gene Network, Genedata, GeneStudio, Geneva Bioinformatics, GenomeQuest, Genomining, Genzyme, Geospiza, Golden Helix, Grace Bio-Labs, High Throughput, Imgenex, INCOGEN, InforSense, Ingenuity, Integromics, Ipsen, Koada Technology, KOOPrime, LINCO, Luminex, MDS, Meso Scale Discovery, MicroDiscovery, Millennium, MiraiBio, Molecular Connections, Monograms, Multimetrix, NetGenics, NextGen, Nonlinear Dynamics, Novartis, Osmetech, Oxonica, Panomics, Partek, Perlegen, PharmaSeq, Predictive Patterns, Proceryon, ProteinOne, Proteome, Radix BioSolutions, RayBiotech, Reel Two, Rescentris, Rosetta Biosoftware, SAS, Semantx Life, Softberry, SoftGenetics, Spotfire, SPSS, Sun Microsystems, SurroMed, Tepnel, Teranode, TG Services, Thermo Fisher, TimeLogic, Tyrian, ViaLogy, Wyeth, Zeus and Zyagen.
Companion Biomarkers in Drug Development

Companion Biomarkers in Drug Development

Publish date : August 2013
Report code : ASDR-75849
Pages : 356

ASDReports.com contact: S. Koomen

ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216

 back to News